Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology

Hormone receptor-positive/HER2-negative breast cancer evolves in response to therapy, demanding smarter, adaptive biomarker-based treatment strategies. We review emerging dynamic biomarkers to guide therapeutic decision-making, spanning tissue and liquid biopsies, metabolic imaging, and microbiome p...

Full description

Bibliographic Details
Authors: Grazia, Giuseppe Di, Schettini, Francesco, Sánchez Bayona, Rodrigo, Casals Pascual, Climent, Pascual, Tomás, Generali, Daniele, Gennari, Alessandra, Vigneri, Paolo, Harbeck, Nadia, Cortés, Javier, Prat Aparicio, Aleix
Format: article
Status:Published version
Publication Date:2026
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:dnet:recercat____::f569258c3000f670365c641ee3ac14d7
Online Access:https://hdl.handle.net/2445/229253
Access Level:Open access
Keyword:Assaigs clínics de medicaments
Càncer de mama
Hormonoteràpia
Drug testing
Breast cancer
Hormone therapy
Description
Summary:Hormone receptor-positive/HER2-negative breast cancer evolves in response to therapy, demanding smarter, adaptive biomarker-based treatment strategies. We review emerging dynamic biomarkers to guide therapeutic decision-making, spanning tissue and liquid biopsies, metabolic imaging, and microbiome profiling, that capture tumor or host-related changes over time. By contrasting Academic and Industry approaches, we advocate for a cultural shift in clinical trial design and implementation, aiming to move from reactive to proactive Oncology.

Similar Items